Industry: Pharmaceuticals, Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda’s second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for chronic sleep disorders. Vanda’s third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness and will be ready to begin a Phase II clinical trial in mid-2007. ( www.vandapharma.com )
Vanda Pharmaceuticals Inc.
9605 Medical Center Drive Suite 300
Rockville, Maryland 20850
USA
Tel: (240) 599-4500
Fax: (301) 294-1900